Pleasanton-based Thoratec Corporation will be participating in two upcoming investor conferences this month, starting with the Raymond James 36th Annual Institutional Investors Conference in Orlando, Florida today.
At that conference, Taylor C. Harris, Vice President and Chief Financial Officer, will provide an update on the company. , beginning at 8:40 a.m., Eastern Standard Time (5:40 a.m., Pacific Standard Time). A webcast of the presentation will be available beginning at 5:40 a.m. Pacific time at http://wsw.com/webcast/rj95/thor, or on the company's website at http://www.thoratec.com/
On Tuesday, March 10, Thoratec will participate in the Barclays Global Healthcare Conference in Miami. The presentation by Taylor C. Harris, Vice President and Chief Financial Officer, will begin at 11:50 a.m. Pacific Daylight Time. A webcast of the presentation will be available at http://cc.talkpoint.com/barc002/031015a_ae/?entity=16_RX0VOBX, or on the company's website at http://www.thoratec.com/
Thoratec is a world leader in therapies to address advanced-stage heart failure. The company's products include the HeartMate II® and HeartMate III(TM) LVAS (Left Ventricular Assist Systems) and Thoratec® VAD (Ventricular Assist Device) with more than 20,000 devices implanted in patients suffering from heart failure.
Thoratec also manufactures and distributes the CentriMag®, PediMag®/PediVAS®, and HeartMate PHP(TM) product lines. HeartMate III is an investigational device and is limited by US law to investigational use. HeartMate PHP is currently in development and not approved for sale.
Thoratec is headquartered at 6035 Stoneridge Drive in Pleasanton. For more information, visit the company's website at http://www.thoratec.com/